Innovations in Chronic Pain Therapeutics
White Mountain Pharma Inc. (WMP) has discovered new mechanisms and a novel approach to treat chronic pain in patients with fibromyalgia, an FDA approved model for chronic widespread pain. After formulating a transdermal testosterone gel uniquely designed for women, White Mountain Pharma has demonstrated efficacy and safety in a Phase I/II study at Dartmouth.
White Mountain Pharma has assembled an experienced team, compiled an extensive patent portfolio, and held a pre-IND meeting with the FDA that confirmed WMP’s approach and endorsed WMP’s Phase II protocol and plan for continued clinical development. White Mountain Pharma holds an extensive and deep portfolio of patent protection for its technology.
White Mountain Pharma has significant experience in the neuroendocrinology of reproductive immunology, particularly with respect to chronic pain and the interaction between reproductive steroid hormones (testosterone/androgens, estrogens and progestins), the immune system and stress responses.
White Mountain Pharma’s approach was enthusiastically received at an Eastern Pain Association invited talk given by Dr. Hillary White, CSO of White Mountain Pharma and Adjunct Professor at Geisel School of Medicine at Dartmouth.”